Compliance Rate
Compliance Rate
0%
Compliant submissions
0
Incompliant submissions
0
Total trials
0
My Organizations' Clinical Trials
Showing 3 of 3 entries
View as:
Phase: N/A
Priority: Normal
Start: 04/30/22
End: 12/31/33
Due: 12/31/34
Phase: N/A
Priority: Normal
Start: 09/04/19
End: 11/15/22
Due: 11/15/23
Phase: N/A
Priority: Normal
Start: 05/12/21
End: 06/30/25
Due: 06/30/26
| Title | NCT ID | Organization | User | Status | Start Date | End Date | Reporting Due Date | Last Checked | User Role | Org Created |
|---|---|---|---|---|---|---|---|---|---|---|
| ChemoRadiation And Tislelizumab for Esophageal/EGJ Cancer | NCT05245760 | Zhonglin Hao | user2@example.com | None | 2022-04-30 | 2033-12-31 | 2034-12-31 | - | - | 2025-07-14 |
| Combination Rucaparib With Nivolumab in Small Cell Lung Carcinoma | NCT03958045 | Zhonglin Hao | user2@example.com | None | 2019-09-04 | 2022-11-15 | 2023-11-15 | - | - | 2025-07-14 |
| Lung Cancer With Copanlisib and Durvalumab | NCT04895579 | Zhonglin Hao | user2@example.com | None | 2021-05-12 | 2025-06-30 | 2026-06-30 | - | - | 2025-07-14 |